Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study
Authors
Keywords
-
Journal
Cardiovascular Diabetology
Volume 19, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-03-05
DOI
10.1186/s12933-020-01002-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes
- (2019) Anastasia-Stefania Alexopoulos et al. Current Diabetes Reports
- Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis
- (2019) Satoshi Ida et al. Cardiovascular Diabetology
- Estimated legacy effects from simulated post-trial data were less biased than from combined trial/post-trial data
- (2019) Lin Zhu et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential
- (2019) Jean-Charles Fruchart et al. Cardiovascular Diabetology
- Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study
- (2019) Nam Hoon Kim et al. BMJ-British Medical Journal
- Altered Risk for Cardiovascular Events With Changes in the Metabolic Syndrome Status
- (2019) Sehoon Park et al. ANNALS OF INTERNAL MEDICINE
- Predicting the Effect of Fenofibrate on Cardiovascular Risk for Individual Patients With Type 2 Diabetes
- (2018) Charlotte Koopal et al. DIABETES CARE
- Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study
- (2018) Aruna D. Pradhan et al. AMERICAN HEART JOURNAL
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
- (2018) Scott M. Grundy et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes
- (2017) Marshall B. Elam et al. JAMA Cardiology
- Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart DiseaseCLINICAL PERSPECTIVE
- (2016) Wendy E. Hague et al. CIRCULATION
- Low Nonfasting Triglycerides and Reduced All-Cause Mortality: A Mendelian Randomization Study
- (2014) M. Thomsen et al. CLINICAL CHEMISTRY
- Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial
- (2014) Karen L. Margolis et al. DIABETES CARE
- Mendelian randomization of blood lipids for coronary heart disease
- (2014) Michael V. Holmes et al. EUROPEAN HEART JOURNAL
- Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation
- (2013) Anette Varbo et al. CIRCULATION
- Fenofibrate
- (2011) Gillian M. Keating American Journal of Cardiovascular Drugs
- Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis
- (2011) Meng Lee et al. ATHEROSCLEROSIS
- Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges
- (2011) Uchechukwu K. Sampson et al. Current Atherosclerosis Reports
- Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Fibrates Effect on Cardiovascular Risk Is Greater in Patients With High Triglyceride Levels or Atherogenic Dyslipidemia Profile: A Systematic Review and Meta-analysis
- (2010) Eric Bruckert et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial
- (2010) Paul M Ridker et al. LANCET
- Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
- (2010) Min Jun et al. LANCET
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Dyslipidemia in type 2 diabetes mellitus
- (2009) Arshag D Mooradian Nature Reviews Endocrinology
- The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia
- (2008) Jean-Charles Fruchart et al. AMERICAN JOURNAL OF CARDIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started